DWA
SCPH

Dorsey Wright & Associates’s scPharmaceuticals SCPH Stock Holding History

Dorsey Wright & Associates’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,300
Closed -$33.6K – 322
2023
Q2 		$33.6K Buy
3,300
+330
+11% +$3.44K 0.01% 165
2023
Q1 		$26.9K Sell
2,970
-330
-10% -$2.42K 0.01% 173
2022
Q4 		$23.7K Buy
+3,300
New +$20.2K 0.01% 234

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Dorsey Wright & Associates's SCPH Position: Q3 2023 in Review

Dorsey Wright & Associates sold out of scPharmaceuticals (SCPH) in Q3 2023, closing a stake of 3,300 shares — an estimated $33.6K sold.

Dorsey Wright & Associates first reported a position in SCPH in Q4 2022 and held it in 3 quarters. The position peaked at $33.6K in Q2 2023. 73 funds tracked by Wall St. Rank hold SCPH as of Q3 2023.

  • Dorsey Wright & Associates reported no remaining scPharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 3,300 scPharmaceuticals shares in Q3 2023, an estimated $33.6K.
  • Dorsey Wright & Associates first reported a position in scPharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Dorsey Wright & Associates's scPharmaceuticals position peaked at $33.6K in Q2 2023.
  • 73 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2023.

Based on Dorsey Wright & Associates's 13F filing for Q3 2023, filed 7 Nov 2023.